Calcitonin for treatment of osteoporosis increased risk for cancer
The European Medicines Agency (EMA) equivalent of the United States food and drug administration yesterday recommended withdrawing calcitonin nasal spray (in the European Union as a treatment for osteoporosis) because of an increased risk for cancer. EMA also noted that long-term use of drugs containing calcitonin (injections or infusion) would increase the risk of... View more